Slimming drug concept stocks fell as Roche announced positive phase 1 results for its GLP-1/GIP new drug

Viking Therapeutics fell 3.22%, Eli Lilly fell 1.4%, Amgen fell 1.34%, and Novo Nordisk fell 1.25%.

Viking Therapeutics fell 3.22%. Eli Lilly fell 1.4%. Amgen fell 1.34%. Novo Nordisk fell 1.25%.
On the news, Swiss competitor Roche announced that its Phase 1 trial of its GLP-1/GIP dual receptor agonist CT-388 in obese people achieved positive results.
Subcutaneous injection of CT-388 once weekly for 24 weeks in healthy obese adults resulted in significant weight loss compared to placebo. The mean placebo-adjusted weight loss rate was 18.8% (p-value < 0.001). Statistical achieved scientific and clinical significance.

Like (0)
Previous May 16, 2024 11:24 pm
Next May 16, 2024 11:24 pm

Related posts